Skip to search formSkip to main contentSkip to account menu

PRM-151

Known as: PRM-151/PTX2, Recombinant Human PTX2, Recombinant Human Serum Amyloid P/Pentraxin 2 
A fully recombinant form of the human pentraxin 2 (PTX2) protein with potential antifibrotic activity. Upon intravenous administration, recombinant… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Homeodomain ProteinsRecombinant ProteinsSerum Amyloid P-Component

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
S828 A RANDOMIZED, DOUBLE BLIND PHASE 2 STUDY OF 3 DIFFERENT DOSES OF PRM-151 IN PATIENTS WITH MYELOFIBROSIS WHO WERE PREVIOUSLY TREATED WITH OR INELIGIBLE FOR RUXOLITINIB
2018
2018
PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study
Introduction: PRM-151, a recombinant human pentraxin-2 molecule, has been shown to prevent and reverse fibrosis in animal… 
Review
2018
Review
2018
Management of Myelofibrosis-Related Cytopenias
Purpose of ReviewCytopenias, particularly anemia, are frequently encountered in patients with myelofibrosis. Management of… 
2016
2016
Pentraxin-2 suppresses c-Jun/AP-1 signaling to inhibit progressive fibrotic disease.
Pentraxin-2 (PTX-2), also known as serum amyloid P component (SAP/APCS), is a constitutive, antiinflammatory, innate immune… 
Review
2015
Review
2015
PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks
Background: PRM-151 (PRM) is a recombinant form of pentraxin-2, an endogenous human protein that acts at sites of tissue damage… 
2014
2014
Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results
PRM-151 (PRM) is a recombinant form of Pentraxin-2, an endogenous human protein that acts at sites of tissue damage, inducing… 
Review
2014
Review
2014
Rationale for combination therapy in myelofibrosis.
2014
2014
Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results.
7114 Background: PRM-151 (PRM) is a recombinant form of Pentraxin-2, an endogenous human protein that acts at sites of tissue… 
2013
2013
Characterization and stabilization of recombinant human protein pentraxin (rhPTX-2).
The potential human therapeutic protein pentraxin (PTX-2) is a large, glycosylated plasma protein consisting of five monomers… 
2011
2011
Monocyte development inhibitor PRM-151 decreases corneal myofibroblast generation in rabbits.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)